LACTOLOGY FOUNDATION

Omeprazole (ATC A02BC01) is a proton pump inhibitor used for acid-related disorders; current human data suggest low fetotoxic and lactotoxic risk at standard doses, with generally compatible use in breastfeeding despite measurable milk transfer.

Pharmacological class and indications

Omeprazole is a substituted benzimidazole that irreversibly inhibits the gastric H+^++/K+^++-ATPase in parietal cells, suppressing basal and stimulated gastric acid secretion. It is indicated for erosive or ulcerative gastritis, gastroesophageal reflux disease (GERD), peptic ulcer disease including Helicobacter pylori eradication regimens, prevention of stress-related mucosal ulcers in high-risk patients, and hypersecretory conditions such as Zollinger–Ellison syndrome. Omeprazole is commonly coded as A02BC01 when used as a single active substance according to the ATC system.wikipedia+3

General toxicology and adverse effects

Omeprazole is generally well tolerated, but acute adverse effects include headache, dizziness, confusion, gastrointestinal symptoms (nausea, vomiting, flatulence, diarrhea including Clostridioides difficile-associated disease), chest pain, allergic reactions, and flushing. Important less frequent toxicities with prolonged use include hypomagnesemia (which can potentiate digitalis toxicity), vitamin B12 deficiency, acute interstitial nephritis, increased fracture risk, and rare reports of gynecomastia. Chronic acid suppression may modify gut microbiota and predispose to enteric infections; long-term risk–benefit assessment is recommended, especially beyond 8–12 weeks of continuous therapy.ncbi.nlm.nih+5

Drug interactions and metabolic considerations

Omeprazole is extensively metabolized by hepatic CYP450 isoenzymes, exhibiting genetic polymorphism in metabolism and numerous clinically relevant interactions. It may increase exposure or effect of diazepam, phenytoin, some antifungals, digoxin, cyclosporine, tacrolimus, saquinavir and some newer oral anticoagulants, and may reduce absorption of drugs requiring an acidic gastric pH such as ketoconazole, itraconazole, some iron preparations, ampicillin, and mycophenolate mofetil. Omeprazole can also reduce the clinical effect of atazanavir, nelfinavir, rifampin, and especially clopidogrel through CYP2C19-mediated interaction, so concomitant use with clopidogrel should be carefully evaluated or avoided.pubmed.ncbi.nlm.nih+3

Pharmacokinetics relevant to pregnancy and lactation

Omeprazole is rapidly and almost completely absorbed, with oral bioavailability around 30–40% due to first-pass metabolism and a high degree (about 95%) of plasma protein binding. It distributes preferentially to gastric parietal cells and undergoes intensive hepatic metabolism, with metabolites eliminated in urine and bile; the high protein binding limits free drug available for placental or mammary transfer. The molecular weight (~345 Da) allows passage into breast milk, but measured milk levels are low, with peak concentrations reported at less than 7% of maternal serum levels, corresponding to an estimated relative infant dose around 1–1.1%.breastfeeding-and-medication+4

Pregnancy: teratogenic and fetotoxic risk

Historically, omeprazole was classified as FDA pregnancy category C, but more recent human observational data show no significant increase in major congenital malformations, miscarriage, preterm birth, or low birth weight compared with disease or drug controls. Large cohort and registry analyses of hundreds of pregnancies exposed to omeprazole or other proton pump inhibitors (PPIs) have not demonstrated a teratogenic signal, suggesting that PPIs, including omeprazole, are not major human teratogens when used at therapeutic doses. Current evidence supports cautious use of omeprazole during pregnancy when clinically indicated, after failure of non-pharmacological and safer pharmacological alternatives (e.g., antacids, alginates, H2_22​-receptor antagonists), with individualized risk–benefit assessment.sps+3

Lactation: transfer into milk and infant exposure

Limited pharmacokinetic data demonstrate that omeprazole appears in breast milk in small quantities, with milk levels much lower than maternal plasma levels and an estimated relative infant dose of approximately 1–1.1%, which is well below the commonly accepted 10% safety threshold. The drug is acid-labile and formulations are gastro-resistant; any omeprazole ingested via milk is likely to be largely destroyed in the infant’s stomach before systemic absorption, further reducing effective exposure. Case reports and clinical experience have not identified adverse effects in breastfed infants of mothers taking standard doses (e.g., 20 mg/day), and several expert sources consider omeprazole compatible with breastfeeding.midlandsmedicines+4

Lactation: theoretical risks and clinical precautions

From a theoretical toxicological perspective, even low omeprazole levels in milk could transiently reduce gastric acidity in the neonate, whose gastric mucosa is particularly sensitive; this underlies a cautious stance in some expert opinions. Potential consequences of sustained acid suppression in infants could include altered digestion, changes in gut flora, and increased susceptibility to enteric infections, although such effects have not been documented in the sparse clinical data from maternal omeprazole exposure via milk. In practice, if a PPI is deemed necessary in a breastfeeding mother, many lactation and medicines information services recommend omeprazole or pantoprazole as PPIs of choice, used at the lowest effective dose with monitoring of the infant for gastrointestinal symptoms, poor weight gain, or unusual irritability.pmc.ncbi.nlm.nih+5

Clinical recommendations in pregnancy and lactation

During pregnancy, omeprazole should be reserved for clear indications such as persistent GERD or ulcer disease not controlled by lifestyle modification and first-line medicines, using the minimal effective dose and duration, with preference for monotherapy (single active substance A02BC01 preparations). In lactation, current international data support that omeprazole is generally compatible with breastfeeding; however, an individualized toxicological–lactological assessment should include the age and health of the infant (particularly preterm or medically fragile infants), maternal dosing regimen, and availability of alternatives. If therapy is initiated or continued in a breastfeeding mother, strategies such as dosing immediately after a feed and using once-daily regimens may further minimize peak infant exposure, though this is largely theoretical given already low milk levels.hpra+5

Summary classification for A02BC01 (omeprazole) in toxico-lactology

On the basis of contemporary human data, omeprazole (A02BC01) can be characterized as non-teratogenic in humans at standard doses, with no clear association with major fetal malformations or adverse pregnancy outcomes, although long-term safety data remain more limited than for older drugs. For lactation, despite demonstrable but low transfer into breast milk and theoretical concerns about neonatal gastric acid suppression, most up-to-date lactation resources classify omeprazole as compatible or low-risk during breastfeeding, particularly when the infant is healthy and term, which contrasts with older, more restrictive categorizations. Clinical decisions should integrate these data with individual patient factors and emphasize shortest effective duration, careful attention to drug interactions, and ongoing monitoring for both maternal and infant adverse effects.ubiehealth+6